Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. 2008

Ixchel Herrera-Guzmán, and Esteve Gudayol-Ferré, and Jennifer Lira-Mandujano, and Jorge Herrera-Abarca, and Daniel Herrera-Guzmán, and Karina Montoya-Pérez, and Joan Guardia-Olmos
Clínica de Enfermedades Crónicas y de Procedimientos Especiales, Morelia, Michoacán, Mexico. iherrera@zeus.umich.mx

Cognitive effects of antidepressants and cognitive predictors of antidepressant treatment response are recent focuses of interest in the neuropsychology of depression. We studied the cognitive predictors of treatment response to bupropion and its neuropsychological effects in patients with major depressive disorder. Twenty subjects meeting the DSM-IV criteria for major depressive disorder were assessed with the Hamilton Depression Rating Scale and a neuropsychological battery. Subjects were medicated with 150 mg/day of bupropion sustained release for 8 weeks. At the end of the trial, 12 subjects were classified as responders to treatment and 8 were non-responders. Our findings suggest that low pretreatment measures of visual memory and low levels of mental processing speed are predictive of good response to bupropion. The cognitive effects of bupropion after the treatment showed that patients improved in visual memory measures and in mental processing speed. Our results suggest that cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder could be closely related. These findings need to be replicated due to the exploratory nature of the present work.

UI MeSH Term Description Entries
D008297 Male Males
D009483 Neuropsychological Tests Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury. Aphasia Tests,Cognitive Test,Cognitive Testing,Cognitive Tests,Memory for Designs Test,Neuropsychological Testing,AX-CPT,Behavioral Assessment of Dysexecutive Syndrome,CANTAB,Cambridge Neuropsychological Test Automated Battery,Clock Test,Cognitive Function Scanner,Continuous Performance Task,Controlled Oral Word Association Test,Delis-Kaplan Executive Function System,Developmental Neuropsychological Assessment,Hooper Visual Organization Test,NEPSY,Neuropsychologic Tests,Neuropsychological Test,Paced Auditory Serial Addition Test,Repeatable Battery for the Assessment of Neuropsychological Status,Rey-Osterrieth Complex Figure,Symbol Digit Modalities Test,Test of Everyday Attention,Test, Neuropsychological,Tests, Neuropsychological,Tower of London Test,Neuropsychologic Test,Test, Cognitive,Testing, Cognitive,Testing, Neuropsychological,Tests, Cognitive
D010054 Brief Psychiatric Rating Scale A scale comprising 18 symptom constructs chosen to represent relatively independent dimensions of manifest psychopathology. The initial intended use was to provide more efficient assessment of treatment response in clinical psychopharmacology research; however, the scale was readily adapted to other uses. (From Hersen, M. and Bellack, A.S., Dictionary of Behavioral Assessment Techniques, p. 87) Overall and Gorham Brief Psychiatric Rating Scale,Overall-Gorham Brief Psychiatric Rating Scale,Overall Gorham Brief Psychiatric Rating Scale
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D003072 Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment. Overinclusion,Disorder, Cognition,Disorders, Cognition
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

Ixchel Herrera-Guzmán, and Esteve Gudayol-Ferré, and Jennifer Lira-Mandujano, and Jorge Herrera-Abarca, and Daniel Herrera-Guzmán, and Karina Montoya-Pérez, and Joan Guardia-Olmos
January 2024, American journal of therapeutics,
Ixchel Herrera-Guzmán, and Esteve Gudayol-Ferré, and Jennifer Lira-Mandujano, and Jorge Herrera-Abarca, and Daniel Herrera-Guzmán, and Karina Montoya-Pérez, and Joan Guardia-Olmos
April 2018, International journal of environmental research and public health,
Ixchel Herrera-Guzmán, and Esteve Gudayol-Ferré, and Jennifer Lira-Mandujano, and Jorge Herrera-Abarca, and Daniel Herrera-Guzmán, and Karina Montoya-Pérez, and Joan Guardia-Olmos
January 2007, International journal of psychiatry in medicine,
Ixchel Herrera-Guzmán, and Esteve Gudayol-Ferré, and Jennifer Lira-Mandujano, and Jorge Herrera-Abarca, and Daniel Herrera-Guzmán, and Karina Montoya-Pérez, and Joan Guardia-Olmos
November 2018, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology,
Ixchel Herrera-Guzmán, and Esteve Gudayol-Ferré, and Jennifer Lira-Mandujano, and Jorge Herrera-Abarca, and Daniel Herrera-Guzmán, and Karina Montoya-Pérez, and Joan Guardia-Olmos
January 2022, Frontiers in psychiatry,
Ixchel Herrera-Guzmán, and Esteve Gudayol-Ferré, and Jennifer Lira-Mandujano, and Jorge Herrera-Abarca, and Daniel Herrera-Guzmán, and Karina Montoya-Pérez, and Joan Guardia-Olmos
May 2012, Journal of psychopharmacology (Oxford, England),
Ixchel Herrera-Guzmán, and Esteve Gudayol-Ferré, and Jennifer Lira-Mandujano, and Jorge Herrera-Abarca, and Daniel Herrera-Guzmán, and Karina Montoya-Pérez, and Joan Guardia-Olmos
May 1988, Biological psychiatry,
Ixchel Herrera-Guzmán, and Esteve Gudayol-Ferré, and Jennifer Lira-Mandujano, and Jorge Herrera-Abarca, and Daniel Herrera-Guzmán, and Karina Montoya-Pérez, and Joan Guardia-Olmos
January 2008, CNS drugs,
Ixchel Herrera-Guzmán, and Esteve Gudayol-Ferré, and Jennifer Lira-Mandujano, and Jorge Herrera-Abarca, and Daniel Herrera-Guzmán, and Karina Montoya-Pérez, and Joan Guardia-Olmos
March 2003, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists,
Ixchel Herrera-Guzmán, and Esteve Gudayol-Ferré, and Jennifer Lira-Mandujano, and Jorge Herrera-Abarca, and Daniel Herrera-Guzmán, and Karina Montoya-Pérez, and Joan Guardia-Olmos
November 2023, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology,
Copied contents to your clipboard!